Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives.
Treatment of [3H]arachidonic acid [( 3H]C20:4)-labeled and antibody-sensitized Ehrlich ascites tumor cells with guinea pig or rabbit serum complement (C) released up to about 20 or 25% of the incorporated [3H]C20:4 into the aqueous phase as a consequence of C-induced hydrolysis of cellular phospholipid. The dose-response curve of release of [3H]C20:4 from Ehrlich ascites tumor cells, with respect to C, was approximately in the same range as the cytolytic response. In the case of [3H]C20:4-labeled and antibody-sensitized peritoneal mouse macrophages, treatment with C induced release of about 11% of the incorporated 3H as C20:4 and about 6% as prostaglandins, thromboxane B2, and hydroxyicosatetraenoic acids. C6- and C8-deficient rabbit and human sera, respectively, induced release of small amounts of [3H]C20:4 from Ehrlich ascites tumor cells and macrophages; these deficient sera also released traces of oxygenated derivatives from macrophages. Addition of purified C6 or C8 effectively restored release from both cell types, indicating that the terminal C proteins, up to and including C8, are required for the major part of the release. Our results do not rule out a possible requirement for C9.
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D002286:Carcinoma, Ehrlich Tumor / Q000503:physiopathology; D002470:Cell Survival; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000502:physiology*; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D008264:Macrophages / Q000502:physiology*; D008563:Membrane Lipids / Q000378:metabolism*; D051379:Mice; D010740:Phospholipases / Q000378:metabolism
D001095:Arachidonic Acids; D015938:Complement Membrane Attack Complex; D008563:Membrane Lipids; D016718:Arachidonic Acid; D003165:Complement System Proteins; D010740:Phospholipases